Recipient mHag-HA1 disparity and aGVHD in thalassemic-transplanted patients.
In order to determine the influence of HA-1 minor histocompatibility antigen mismatch on BMT outcome, we analyzed a pool of 94 thalassemic transplanted patients all selected for the presence of HLA-A(*)0201 allele. The HA-1 typing was performed using SSP analysis. All the patients received bone marrow from HLA-identical MLC nonresponsive siblings. As graft-versus-host-disease (GVHD) prophylaxis, all patients received cyclosporin and short methotrexate. Grades II-IV GVHD occurred in five (33.3%) of the 15 patients with recipient HA-1 disparity compared with 14 (17.7%) of the 79 patients without HA-1 disparity. Despite the higher incidence of acute graft-versus-host-disease (aGVHD) in the group of patients with HA-1 incompatibility, these data were not statistically significant. However, it was interesting to observe that no GVHD developed in any of the 15 cases in which the recipient was HA-1 negative and the donor HA-1 positive.
Nesci
S
S
Laboratorio de Ricerca Onco-Ematologico, Dipartimento di Onco Ematologia, Pesaro, Italy.
Buffi
O
O
Iliescu
A
A
Andreani
M
M
Lucarelli
G
G
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005838:Genotype; D006086:Graft vs Host Disease / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008297:Male; D015778:Minor Histocompatibility Antigens / Q000235:genetics / Q000276:immunology*; D009842:Oligopeptides / Q000235:genetics / Q000276:immunology*; D035781:Siblings; D013789:Thalassemia / Q000628:therapy*
C110615:HA-1 antigen; D015778:Minor Histocompatibility Antigens; D009842:Oligopeptides